Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Big R&D Investment Trend as Mid-Cap Biotechs Push to Get Drugs to Market

Published: Thursday, March 07, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
20% of overall increase in R&D expenditure in just a year.

Biotech firms eager to push drug candidates through clinical trials prompted an overall increase in R&D expenditure of 20% in just a year, states research and consulting firm GlobalData.

GlobalData’s new report, which compares the competitive position of 15 innovative mid-cap biotech companies on 20 financial metrics, states that the peer group R&D spend for Q3 2012 reached US$746.8m, climbing from US$621.1m in Q3 2011.

“Oncology is the main focus of biotech R&D activities,” says Adam Dion, GlobalData’s Analyst covering Healthcare Industry Dynamics, “which is driving peer group R&D expenses higher.”

Regeneron was the firm with the highest R&D expenditure for Q3 2012, with an outlay of US$158m.

According to the report, Regeneron’s R&D spend has increased steadily each quarter since Q3 2011, when the total stood at US$128m.

“Biotech companies are becoming increasingly more successful at developing innovative therapies,” says Dion. “However, our research has found that the high cost of bringing these therapies to market continues to erode corporate profitability.”

In terms of percentages, ViroPharma displayed the biggest year-to-year drop in R&D expenditure.

The company’s R&D spending plummeted 28% year-to-year, from US$22.9m in Q3 2011 to US$16.5m in Q3 2012.

The decrease in ViroPharma’s R&D spend was caused by the Food and Drug Administration’s suspension of the company’s clinical trials of its flagship product Cinryze due to safety concerns.

“The FDA put a hold on two of the company’s Phase II clinical studies when trials revealed elevated antibody levels detected in the treatment arm of the study,” explains Dion. “These concerns have since been addressed and, with FDA approval, the firm resumed the trials in September of last year.”

As defined by a proprietary ratings system based on a number of financial metrics including revenue, sales growth and cost containment, GlobalData identified Regeneron as the peer group benchmark leader in the third quarter, overtaking the Q2 2012 number one, Alexion.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tofacitinib: Sacrificing Safety for Novelty?
FDA has extended the review period of tofacitinib by three months.
Wednesday, August 22, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos